BioCryst (BCRX) Pharmaceuticals announced that it has successfully completed the previously announced sale of its European ORLADEYO business to Neopharmed Gentili. Transaction Details: BioCryst received $250 million upfront for the European assets and rights related to ORLADEYO and may receive up to $14 million in future milestones associated with sales in Central and Eastern Europe. Purchase price reflects a highly attractive multiple of approximately 5.4 times sales over the last twelve months ending June 2025. Global ORLADEYO revenues earned by both BioCryst and Neopharmed Gentili will be aggregated to determine the royalty rate thresholds for both the RPI and OMERS royalties and the cumulative cap on the OMERS royalty. Each company will pay royalties in proportion to its share of global revenues at the aggregate rate.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst reports inducement grants under Nasdaq listing rule
- BioCryst’s Chief R&D Officer Resigns Amid CEO Decision
- BioCryst announces departure of CRDO Helen Thackray
- BioCryst’s BCX17725: A Promising Step Forward in Treating Netherton Syndrome
- BioCryst’s Earnings Call Highlights Strong Growth and Strategic Moves